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Errata 
Page 10, line 22: …which I usually received the day after I sent him 
the manuscript with, changes …. Changed to: …which I usually 
received the day after I sent him the manuscript, with changes…. 
Page 12, line 8: Finally, lena Tjeldhorn, MSc…… changed to: Lena 
Tjeldhorn, MSc…. 
Page 12, after line10: Insert a new sentence: Finally, Heidi 
Johansen, MSc, has been central in the statistical analysis of the SF- 
36 data. 
Page 16, line 5: …Hald JK, Lilleas FG…changed to: …Hald JK, 
Lilleås FG… 
Page 36, end of text: End sentence with a period: ….among 
carriers of the same mutation. 
Page 46, line 16: …We cannot exclude the possibility that the 10 GC 
positive….changed to: …We cannot exclude the possibility that the 
11 GC positive….. 
Page 61, line 26: We included a search for investigation for 
mutations in… changed to: We included a search for mutations in… 
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Abstract 
Background: A large proportion of patients with Marfan syndrome (MFS) 
complain of fatigue and of reduced physical capacity and endurance. By 
virtue of medication, life style adaptation and aortic surgery, persons with 
MFS now live longer. Thus, knowledge about the human consequences of 
MFS is becoming increasingly important. As the diagnosis of MFS is 
challenging, we understood that we first had to verify the presence of the 
syndrome, then to explore its human consequences. 
Aims: To explore the FBN1 genotype and phenotype in accordance with 
the present diagnostic criteria for MFS, the Ghent criteria (GC), by 
investigating the prevalence of the phenotypic features and their 
consequences for perceived health-related quality of life (HRQOL), and to 
search for correlations between genotype and phenotype in Norwegian 
patients with given or suspected MFS. 
Methods: A cross-sectional study of adults with presumed MFS living in 
Norway, investigated for all features in the GC and assessed regarding self-
reported HRQOL with the help of the health status survey questionnaire SF-
36. 
Results: One hundred and five adults with presumed MFS were examined 
for all features in the GC, and constituted the study populations of paper 1-
3. Eighty-four participants meeting the GC, formed the study population in 
paper 4, addressing HRQOL. 
Of the 105 participants, 87 fulfilled the GC in 56 variants. Among GC-
positive persons, the major dural criterion was found in 91%, the major 
genetic criterion (positive family history and/or FBN1 mutation) in 89%, 
the major ocular criterion in 62 %, the major cardiovascular in 53% and the 
major skeletal in 38%. Seventy-nine per cent fulfilled both the major dural 
and the major genetic criteria. Seventy-three carried an FBN1 mutation, all 
fulfilling the GC. A total of 46 mutations were discovered in 44 unrelated 
participants. Although no statistically significant correlations were found, 
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the results indicate an association between missense mutations affecting a 
cysteine residue and ectopia lentis. Substantial interindividual and 
intrafamilial variation in persons carrying the same mutation complicates 
genetic counselling. In individuals meeting the GC in whom a mutation in 
FBN1 had not been identified, subsequent molecular analysis revealed that 
two of them carried a TGFBR2 mutation and one a TGFBR1 mutation. 
These three persons were classified either as MFS type 2 or Loeys-Dietz 
syndrome type 2.  
Of the 18 persons not meeting the GC, five carried a TGFBR2 mutation and 
was diagnosed as having Loeys-Dietz syndrome type 2, one carried a 
COL3A1 mutation and was diagnosed with Ehlers-Danlos syndrome (EDS), 
vascular type, while one was found to have homocystinuria. Clinically, one 
participant was assessed as having EDS classical type, and four were 
diagnosed with benign joint hypermobility syndrome, now considered to be 
the same as EDS hypermobile type. 
Concerning HRQOL, the 84 participants meeting the GC obtained low 
scores on all eight subscales of SF-36 compared with the general 
Norwegian population. The scores were comparable to scores from 
previous reports on persons with other severe chronic illnesses. In our study 
lower scores than in other studies of MFS were noted for social function, 
vitality, general health, bodily pain and role physical. We found no 
correlations of substantial explanatory value between the SF-36 subscales 
and gender, BMI, ascending aortic surgery, β-blockers, visual acuity, joint 
hypermobility, fulfilling the five major GC, or number of major criteria 
fulfilled.  
Conclusion:  Although our study indicates that close to 80% of all MFS 
patients may be identified through investigation of the dura mater and the 
family/genetic system, investigations of all features of the GC are necessary 
for identifying all persons fulfilling the GC. As a correct diagnosis may be 
crucial for function and life, the clinical variability illustrates the challenge 
facing clinicians in attempts to identify individuals with MFS. The 
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increasing number of known MFS-like disorders with some similar signs 
and symptoms, but different clinical histories makes this challenge even 
greater. 
Comprehensive diagnostics are necessary for an understanding of the 
clinical history of MFS, and a prerequisite for studies of function and the 
human consequences of MFS. Measured with SF-36, the HRQOL seems 
even more reduced in all eight subscales than has been reported from earlier 
studies of small study populations.  
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Abbreviations and selected explanations 
Abbreviation Explanation 
AM Anterior meningocele. Spinal fluid covered with dura 
mater, protruding into the pelvis through enlarged foramina 
or defects in the sacral vertebral bodies 
BJHS Benign joint hypermobility syndrome 
CT Computed tomography 
DE Dural ectasia. Enlargement of the dural sac, primarily in the 
lumbo-sacral area 
DNA Deoxyribonucleic Acid 
DSD Dural sac diameter 
DSR Dural sac ratio: DSD/VBD 
EDS Ehlers-Danlos syndrome 
FBN1 Fibrillin 1. The human gene for fibrillin 1  
GC Ghent criteria 
HRQOL Health-related quality of life 
LDS Loeys-Dietz syndrome 
MASS 
syndrome / 
MASS 
phenotype 
Myopia, mitral valve prolapse, mild aortic dilatation, striae 
and minor skeletal criteria 
MFS Marfan syndrome 
MLPA  Multiplex ligation-dependent probe amplification. Test kit 
designed for detecting large deletions or duplications in 
DNA 
MRI Magnetic resonance imaging 
SF-36 Short form – 36 
PTC Premature termination codon 
TAAD Thoracic aortic aneurysm and dissection 
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TGFBR1 Transforming growth factor β receptor 1. Human gene for 
Transforming growth factor β receptor 1. 
TGFBR2 Transforming growth factor β receptor 2. Human gene for 
Transforming growth factor β receptor 2 
TRS TRS, National Resource Centre for Rare Disorders, 
Sunnaas Rehabilitation Hospital, Nesodden, Norway. 
See www.sunnaas.no/trs  
VBD Vertebral body diameter, measured at mid-corpus level 
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Introduction 
Entering the field of Marfan syndrome 
My first clinical contact with people with Marfan syndrome (MFS) was in 
1992, when I was project director for TRS, a national resource centre for 
rare disorders. Fairly early, the large proportion of MFS patients 
complaining of fatigue and reduced physical capacity and endurance caught 
my interest.  
After many years in rehabilitation medicine, this was a familiar set of 
problems for me. As from 1988, our team at Sunnaas Rehabilitation 
Hospital started to explore this field with focus on persons with post polio 
syndrome, and our first papers on the topic were published in 1991 
[Stanghelle, J. K. et al. 1991; Stanghelle, J. K. and Rand-Hendriksen, S. 
1991]. The team continued their investigations after I started my work at 
TRS. Thus, Sunnaas Rehabilitation Hospital had the scientific and practical 
framework for exploring fatigue and reduced physical capacity and 
endurance in the Marfan population. 
While planning a pilot study on young adults with MFS in 1996, we 
discovered that very few of our MFS patients had been investigated for all 
features in the diagnostic criteria (Berlin criteria) [Beighton, P. et al. 1988]. 
Consequently, we first had to verify the diagnosis before exploring fatigue, 
reduced physical capacity and endurance. At that time we did not have 
access to genetic analysis of the candidate gene for MFS, the gene encoding 
fibrillin-1 (FBN1).  
The pilot study indicated that the diagnosis MFS had been given to five of 
23 persons who did not fulfil either the Berlin criteria or the new diagnostic 
criteria introduced in 1996, the Ghent criteria, [De Paepe, A. et al. 1996]. 
Further, in another four of the same 23 persons fulfilment of one or more 
criteria was questionable (results were presented as posters at the 7th. 
International Symposium on the MFS, 14-17.09.05, Gent, Belgium). 
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Two papers from the pilot study have been published [Giske, L. et al. 2003; 
Rand-Hendriksen, S. et al. 2007]. 
 
These results strengthened my interest in the diagnostics and differential 
diagnosis of MFS and MFS-like disorders. 
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Background 
Marfan syndrome (MFS) 
MFS is a genetic connective tissue disorder with an autosomal dominant 
mode of inheritance [Faivre, L. et al. 2008]. MFS is named after Antoine 
Marfan, a Parisian paediatrician, who in 1896 described a five year old girl 
with long, slender limbs, scoliosis and contractures [Marfan AB 1896]. 
During the first half of the 20th century, a number of features associated 
with MFS were described (mitral regurgitation, lens ectopia, enlarged 
ascending aorta, dissection of the ascending aorta, autosomal dominant 
inheritance, striae, hernia, spontaneous pneumothorax). In 1988 dural 
ectasia was found to be associated with MFS [Pyeritz, R. E. et al. 1988].  
In the early 1950s, Victor A. McKusick used MFS as the example of the 
entity “heritable disorders of connective tissue” [McKusick VA 1956]. In 
1991 it was reported that MFS is a disorder caused by a mutation in the 
gene for fibrillin [Dietz, H. C. et al. 1991]. 
A genetic syndrome is defined as a disorder characterised by the presence 
of a number of different features which are believed to have a common 
cause. MFS is described as a pleiotropic disorder (Greek; pleion= many; 
tropic from tropos = "to turn, to convert") referring to the many different 
organ systems and signs and symptoms mutations in one gene can produce. 
The expressivity is highly variable, as the clinical expression varies widely, 
both between families and within a family. MFS is usually believed to have 
full penetrance [Hutchinson, S. et al. 2003]. A number of the features in the 
GC develop over the years. Skeletal features, lens luxation and a dilated 
ascending aorta may be present at birth, but they usually develop through 
puberty or in young adulthood. The natural history of dural ectasia has not 
been explored. 
As in the case of many rare disorders, most studies on MFS are based on 
small study populations, often recruited from wide and undefined 
populations through fourth level specialist centres. The participants may 
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represent the most severe part of the clinical spectrum [Akutsu, K. et al. 
2009]. In many studies, only one or a few organ systems have been 
explored.  
In this thesis, the natural history of a disorder refers to the course of the 
disorder without medical intervention, whereas the clinical history describes 
its progression with the treatment given at any specified time. 
Routines for treatment and support for any disorder must be based upon 
knowledge about the clinical history of that disorder. A description of the 
clinical history should ideally be based on longitudinal studies of large 
groups of persons with an unambiguous diagnosis, representing all variants 
of the disorder. Based on existing studies, this has not been possible for 
MFS. 
For any disorder, a correct diagnosis is crucial for the understanding of the 
clinical history - and for follow-up and treatment. This is not only true for 
those fulfilling the diagnostic criteria. As pointed out by Raanani and 
Ghosh [Raanani, E. and Ghosh, P. 2008], it is just as important to refute the 
diagnosis, whenever possible, thereby avoiding stigmatisation and the 
burden of follow-ups and lifestyle restrictions that accompany a diagnosis. 
Or, as stated by Arslan-Kirchner et al [Arslan-Kirchner, M. et al. 2008], “If 
a disease or susceptibility to a disease can be specifically excluded, this can 
spare the patient the differential diagnostic procedures and the preventive 
measures, together with the stress which results from these”. 
Until a diagnosis is well defined and a pathognomonic test is found, 
diagnostic criteria have to be used. The description of a clinical entity and 
of diagnostic criteria takes time. However, with increasing knowledge, 
diagnostic criteria are often found to produce false positive and false 
negative results [Arslan-Kirchner, M. et al. 2008]. False positive and false 
negative diagnoses may result in a faulty understanding of the clinical 
history. Therefore, diagnostic criteria need to be revised.    
Over time, some individuals will find that changing sets of criteria gives 
them a diagnosis, only to have it taken away later. This process is 
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frustrating for the patients, and the clinicians and scientists need to be aware 
of this problem.  
 
Diagnostic criteria 
Diagnostic criteria are tools aimed at categorising persons suspected of 
having a diagnosis into either of the two groups: “Fulfilling the criteria, 
having the disorder” and “not fulfilling the criteria, not having the 
disorder”. 
At least three sets of diagnostic criteria for MFS have been presented;  
 1979. Criteria proposed by Pyeritz and McKusick [Pyeritz, R. E. and 
McKusick, V. A. 1979] 
 1986. The Berlin criteria [Beighton, P. et al. 1988]  
 1996. The Ghent criteria (GC) [De Paepe, A. et al. 1996]. 
New additions included in the GC are a major criterion defined in the 
skeletal system and the “presence of a mutation in FBN1 known to cause 
the MFS”, taken in as a major criterion in the family/genetic system.  
The Ghent criteria (GC) 
The GC, also called the Ghent nosology [De Paepe, A. et al. 1996], consists 
of a rather complex set of diagnostic criteria that defines features on four 
levels: “Minor criteria”, “organ systems involved”, “manifestations” and 
“major criteria”. Minor criteria are described for 5 organ systems. When 
minor criteria are fulfilled, they can together add up to fulfil the criterion 
“an organ system involved”. The later criterion is described for five organ 
systems: the skeletal system, the cardiovascular system, the ocular system, 
the lungs, and the skin and integument. In the skeletal system, eight specific 
manifestations are described; when a person fulfils four out of eight 
manifestations, the major skeletal criterion is met. 
Major criteria are described for five organ systems: The skeletal system, the 
cardiovascular system, the ocular system, dura mater and family history / 
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genetics (family history / genetics is counted her as an organ system). See 
Table 1: 
 
Table 1. Organ systems where “involved organ system” and “major 
criteria” are defined in the Ghent criteria.  
  
Organ system Major Involved 
Family / Genetic X - 
Dura X - 
Ocular X x 
Cardiovascular X* x 
Skeletal X* x 
Lungs - x 
Skin and integument - x 
 
* = when fulfilling a major criterion, the organ system is automatically 
involved [De Paepe, A. et al. 1996]  
 
To give an individual the diagnosis of MFS, two major criteria in two 
different organ systems have to be fulfilled and a third organ system must 
be involved.  
For each of the seven organ systems included, the criteria describe variably 
well-defined symptoms and signs; some with given references for cut-off 
values against normality, others not.  
There is no congruency between the different organ systems in the 
construction of the GC. If a person meets the criterion “the ocular system 
involved”, this adds new information about the patient, as it implies having 
at least two of the following: increased axial globe length; abnormally flat 
cornea; hypoplastic iris or ciliary body. On the other hand, “having the 
cardiovascular system involved” may or may not give new information 
about the patient: The cardiovascular system is involved in the presence of 
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at least one major criterion or one minor criterion. As mentioned earlier, the 
features of the skeletal system are organised in a special way. The major 
criterion demands the presence of four out of eight manifestations. The 
skeletal system is involved in the presence of two of the eight 
manifestations or of one manifestation plus two minor criteria. Hence, all 
persons fulfilling the major cardiovascular criterion or the major skeletal 
criterion will have the same organ system involved.  
For further details of the GC, see paper 1, Table 1. 
Prevalence 
Any prevalence reported is dependent on the diagnostic criteria used for the 
investigation. 
The prevalence of MFS is disputed. An often cited prevalence is    
1-2:10,000 inhabitants [Pyeritz, R. E. 2000]. In a recent paper, Rybczynzki 
et al  report on 279 persons suspected of having MFS, all from the Hamburg 
metropolitan area (3.5 million inhabitants) [Rybczynski, M. et al. 2008]. 
They found the prevalence of  “Marfan and Marfan-like syndromes” 
7:100,000, and compared this with the prevalence of 6:100,000 reported by 
Pyeritz and McKusic [Pyeritz, R. E. and McKusick, V. A. 1979]. Arslan-
Kirchner et al [Arslan-Kirchner, M. et al. 2008] refer to von Kodolitsch et 
al, who in a German paper from 2003 have suggested  a prevalence of 
1:3,000. 
Two papers presenting prevalence studies have been found, one reporting a 
prevalence of 6.81:100,000 inhabitants [Gray, J. R. et al. 1994]  in Scotland 
(Berlin criteria), the other a figure of  4.6:100,000 [Fuchs, J. 1997] in 
Denmark (Berlin criteria). We have found no studies giving indications of 
the prevalence in Norway. 
Molecular background 
MFS is described as a fibrillin 1 disorder, typically caused by mutations in 
FBN1 which have been located to 15q21.1. FBN1 is the only gene included 
in the Ghent nosology [De Paepe, A. et al. 1996]. However, FBN1 
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mutations have been discovered in persons representing a wide phenotypic 
spectrum from neonatal MFS to milder forms.  
Except for associations between neonatal MFS and mutations in exons 24 to 
32, genotype – phenotype correlations have been hard to find. 
FBN1 mutations have also been found in individuals not fulfilling the GC 
[Collod-Beroud, G. et al. 2003; Collod-Beroud, G. and Boileau, C. 2002]. 
All persons exhibiting an FBN1 mutation are said to belong to a group 
called “Type 1 fibrillinopathies” or “fibrillin-1-opathies” [Robinson, P. N. 
et al. 2006].  
Genetic heterogeneity 
Genetic heterogeneity in MFS has been discussed since Collod et al (1994) 
reported on a large French family with MFS, in whom a candidate gene on 
a locus on 3p24.2-p25 was indicated [Collod, G. et al. 1994]. For the 
clinician it should be stressed that the diagnostics in MFS must be based 
mainly on clinical examinations, and less on molecular analysis. 
Phenotype  
Most patient cohorts presented in the literature have not undergone 
investigation of all organ features contained in the GC. The presence of 
aortic dilatation is usually reported in all patients, and often the presence of 
lens ectopia. Often examinations are not performed for dural ectasia, 
protrusio acetabuli, minor ocular features, body ratios, degree of scoliosis, 
presence of spondylolisthesis, and blebs in the lungs [Arbustini, E. et al. 
2005; Biggin, A. et al. 2004; Loeys, B. et al. 2004; Rommel, K. et al. 2005]. 
In recent papers based on over 1,000 persons in the FBN1 mutation 
database, it is reported that about 30% of the patients have been 
investigated for dural ectasia and protrusio acetabuli [Faivre, L. et al. 2007; 
Faivre, L. et al. 2008; Faivre, L. et al. 2009b; Stheneur, C. et al. 2009].  
Papers presenting the prevalence of major criteria and of organ systems 
involvement in groups of MFS patients are rare, and only a few of them 
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focus on adults [Grahame, R. and Pyeritz, R. E. 1995; Hasan, A. et al. 2007; 
Rybczynski, M. et al. 2008].  
In different papers, the prevalence reported for each organ systems varies. 
This might be due to the use of different methods of recruiting participants 
to the studies, resulting in selection bias, and by differences in investigation 
methods.  
The diagnostic process – a logistic challenge 
The diagnostic process carried out in accordance with the GC is a logistic 
challenge, a time- and resource-consuming procedure which involves a 
number of medical specialities [Dean, J. C. 2007; Summers, K. M. et al. 
2006]. The process must be started when the diagnosis is suspected. 
Referrals for all investigations have to be written and sent, and results 
collected. When all the results are available, every organ system must be 
assessed in accordance with the criteria, and one should decide whether the 
major criterion is fulfilled or not and whether the organ system is involved 
or not. Finally, counting fulfilled major criteria and involved organ systems, 
the person should be assessed as “fulfilling GC” or “not fulfilling GC”.   
Without a multidisciplinary centre to manage all diagnostics, this is difficult 
to achieve [Faivre, L. et al. 2008].  
The need for studies on the prevalence, and thereby on the sensitivity and 
specificity of the major criteria and involved organ systems, has been 
pointed out [De Paepe, A. et al. 1996; Fattori, R. and Nienaber, C. A. 1999]. 
Only recently, a report has been published on the prevalence, sensitivity and 
specificity of a number of features in the GC in a group of persons 
suspected of having MFS [Rybczynski, M. et al. 2008]. Values for 
compound major criteria fulfilled or compound organ systems involved are 
not presented. For example, they report how many participants had a dilated 
ascending aorta and how many had ascending aortic dissection, but do not 
report how many participants met the major cardiovascular criterion. 
Likewise, they do not give the prevalence of fulfilment of the major skeletal 
criterion or having the skeletal system involved. 
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On the one hand, mutations in FBN1 do not seem to be specific for MFS, 
since a number of papers report on persons with FBN1 mutations not 
fulfilling GC. On the other hand, the clinical criteria are not specific, since 
mutations in a locus on 3p24.2-p25 have been found in persons fulfilling 
the GC [Collod, G. et al. 1994]. The prevalence rates of the major criteria 
and involved organ systems have not been established; hence, the 
sensitivity and specificity of each Ghent feature are not known.  
Thus, there is a need for further studies of groups of patients with MFS, 
with examination of all features, including DNA investigations. Only 
through such a strategy, can the definition of and criteria for MFS be further 
elucidated. Broader descriptive studies are also needed for delineation of 
other genetic connective tissue disorders with overlapping features. 
Health-related quality of life in MFS 
As the lifespan of persons with MFS is getting longer through medication, 
life style adjustments and aortic surgery, there is an increasing need for 
knowledge about how the MFS patients perceive their condition and their 
lives, and what services might improve their situations.  
Investigations of health-related quality of life (HRQOL) in diagnostic 
groups are used for assessing the experienced burden of a diagnosis and for 
developing health care systems addressing the most affected domains of 
life.  
We therefore decided to include a commonly used tool for evaluating self 
reported HRQOL. 
The WHO Quality of Life assessment group defines quality of life as: “The 
individual’s perception of their position in life in the context of the culture 
and value system in which they live and in relation to goals, expectations, 
standards and concerns” [The WHOQOL group 1995]. HRQOL focuses on 
the individual’s satisfaction with or happiness about domains in life that are 
affected by health or health care.  
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In spite of the large number of papers concerning MFS that have been 
published the last two decades, the impact of MFS on HRQOL has rarely 
been explored.  
Peters et al [Peters, K. et al. 2005; Peters, K. F. et al. 2001a; Peters, K. F. et 
al. 2001b; Peters, K. F. et al. 2002] however, have described some aspects 
of the human consequences of living with MFS.  
Three papers on this topic have been published [Foran, J. R. et al. 2005; 
Fusar-Poli, P. et al. 2008; Verbraecken, J. et al. 2001], describing studies 
using a commonly used HRQOL tool for assessment, the Short Form 36 
(see methods page 31). The interpretations of the results of the three studies 
differ. 
 
Studies of perceived HRQOL in groups of adults with verified MFS are 
therefore needed. 
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Aim of the study, hypotheses 
The aim of the study was to explore the FBN1 genotype and phenotype in 
accordance with the GC, to investigate the prevalence of the phenotypic 
features and their consequences for perceived HRQOL, and to search for 
correlations between genotype and phenotype in Norwegian patients with 
given or suspected MFS. 
 
For these purposes, the following hypotheses were tested: 
1. Only a fraction of the presumed MFS population fulfils the 
diagnostic criteria, GC. 
2. Only a fraction of the same population carries a mutation in FBN1. 
3. The fraction fulfilling the GC and the fraction carrying a mutation in 
FBN1 do not consist of the same individuals. 
4. There is a range of disorders of connective tissue and other diseases 
in which some of the features of MFS are present, but where the GC 
are not fulfilled. There is a need for better categorisation and tools 
for the differential diagnostics between the Marfan-like disorders. 
5. People fulfilling the Ghent criteria for MFS report lower HRQOL 
than the general population. 
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Material and methods 
Design 
This investigation is a cross-sectional study of adults (≥ 18 years of age on 
inclusion) with presumed MFS (had been given the diagnosis or suspected 
MFS), living in Norway (Population 4,799,300; September 1. 2009). 
At TRS, which is a national resource centre for seven rare disorders, the 
target groups include the genetic connective tissue disorders osteogenesis 
imperfecta, Ehlers-Danlos syndrome and MFS.  
TRS has established national registers for the diagnostic groups, including 
MFS.  
However, it is the patient who reports for registering.  
Consequently, the validity of the register is dependent on: 
 the quality of the diagnostic work done by the doctors giving the 
diagnosis  
 the knowledge about TRS among persons with a diagnosis 
 the willingness of the patients to register  
Study population 
The participants in this study were recruited either by:  
 Letter of invitation sent to the 134 individuals above 18 years of age 
in the TRS database, who had registered as having MFS. 
 An advertisement in the journal of the Norwegian association for 
MFS and MFS-like disorders, requesting for adult persons who had 
been diagnosed with MFS to participate. 
 Invitations distributed in the Department of Thoracic and 
Cardiovascular Surgery, Rikshospitalet University Hospital, to 
patients with suspected MFS. 
Through the letters of invitation, 80 persons (60%) signed in for 
participation. 
Through the second and third methods, 29 further persons were recruited.  
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As the number of persons reading the MFS journal is not known, the actual 
number of persons informed about the study was unknown.  
A total of 109 individuals gave their informed consent to participate, but 
one died before the study began, one was not able to attend while living 
abroad and two participants withdrew, one before and one during the 
investigations. 
Consequently, the study population consisted of 105 individuals, 67 women 
(64%) of median age 42 years (range 20–69 years) and 38 men (36%) of 
median age 33 years (range 19–62). This cohort constitutes the background 
population for all four papers. 
Ninety of the 105 persons had previously been given a diagnosis of MFS; 
15 persons entered the study because of suspicion of MFS. All participants 
were Caucasian. The 105 individuals represented 66 families. Forty-five 
individuals were the only representatives of their family, whereas 60 
individuals were from 21 families. 
Methods 
To obtain valid results, the examinations were all carried out by the same 
group of investigators and with the same methods.  
The clinical investigators were blinded with respect to the patient’s 
mutational status, while the persons performing the DNA analysis were 
blinded with respect to the patient’s clinical findings. 
As the participants came from all over Norway, all investigations were done 
during a 2-day stay in Oslo through visits in 3 hospitals. 
Clinical features 
A blood sample was taken for measurement of serum homocysteine.  
Skeletal system: Clinical musculoskeletal investigation, inspection, range 
of motion (in accordance to Beighton’s scale), anthropometric 
measurements, scout view of the spine and computed tomography (CT) 
scans of the chest and the acetabuli.  
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Ocular system: Slit lamp investigation, keratometry of the cornea and 
ultrasound investigation of the globe length.  
Cardiovascular system: Echocardiography and magnetic resonance 
imaging (MRI) investigation of the thoracic aorta without contrast. When 
MRI of the cardiovascular system was not possible, CT was used.  
Dural ectasia: MRI of the lumbo-sacral spine, including the distal end of 
the dural sac. When MRI of the spine was not possible, CT was used. 
Skin and integument: Inspection for stretch marks and scars from hernia 
operations. The age of occurrence of stretch marks, and in women, the 
relation to the first pregnancy, was noted. The history of - and scars after - 
operations for hernia were noted. 
Lungs: Blebs were looked for on the CT scans of the chests. A history of 
spontaneous pneumothorax was noted. 
Family/genetic history: The family tree was sketched. Information about 
all first degree relatives was asked for. Relatives who had been given a 
diagnosis of MFS were noted. For each relative, the participants’ 
knowledge about an enlarged or surgically treated ascending aorta, 
dislocated lenses, ophthalmological operations and DNA investigations 
were recorded. All information on each relative was evaluated in 
accordance with the GC. Relatives known to fulfil at least two major 
criteria were recorded as “independently fulfilling the GC”. 
Genotype analysis 
The entire FBN1 coding region was sequenced by means of a robot-assisted 
procedure [Tjeldhorn, L. et al. 2006]. DNA from all participants was 
exposed to a commercially available MLPA kit screening for large 
intragenic or total gene deletions or duplications in FBN1 and TGFBR2. 
The coding part of TGFBR2 was sequenced. Persons in whom no mutations 
were found in FBN1 or in TGFBR2, were investigated for mutations in 
TGFBR1. 
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SF-36 
The Medical Outcome Study (MOS) 36-item Short-Form Health Status 
Survey (SF-36) [Ware, J. E., Jr. and Sherbourne, C. D. 1992] is one of the 
most commonly used generic questionnaires, which is often applied as a 
measure of HRQOL. Therefore, SF-36 was chosen as our study tool for 
assessing self-reported HRQOL. 
There is an ongoing discussion on what is actually measured by SF-36, but 
that debate is beyond the scope of this work. 
The first afternoon during the hospital stay, the participants were given 
instructions about how to fill in the Norwegian translation of the SF-36 
questionnaire, version 1.2; chronic. The questionnaire was handed out, and 
was returned the next morning.  
Ethical and regulatory aspects 
After learning that most persons given the Marfan diagnosis had not been 
investigated regarding the relevant organ systems, we understood that the 
study was needed, and would prove beneficial for the individual participant.  
The study was approved by the regional ethics committee and by the 
Privacy Protection Supervisor. 
After reading the information letter, the participants sent in a signed 
informed consent. If any findings should indicate the need for further 
investigations and/or treatment, the participants in question were referred to 
the relevant clinics. In Norwegian health care, there is a personal proportion 
to pay for health services until a given limit per year has been reached (in 
2009, approximately 200 euro / 300 US dollar per year). All health care for 
the rest of that year is paid for by the national social security system. Thus, 
there are no economic constraints on the individual person for the 
diagnostic process or for receiving therapy. 
As we decided not to administer intravenous contrast agent for the MRI of 
the aorta, none of the investigations entailed any risk for the participant.  
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Evolving knowledge during the study period 
This study was planned in 2002, and the clinical examinations were 
performed through 2003 and 2004. Since the start, papers presenting 
important new knowledge have been published. 
Through studies on mice with FBN1 mutations and MFS, the understanding 
of disturbed TGF-β signalling as part of the aetiology of some, but not all, 
of the organ pathology in MFS  has been established [Neptune, E. R. et al. 
2003]. The pathological process that does not seem to be mediated by TGF- 
β is the degradation of the lens threads, which are almost totally composed 
of fibrillin 1, causing lens luxation [Faivre, L. et al. 2007].  
In 2005, it was documented that mutations in TGFBR2, found in a locus on 
3p24.2-p25, cause thoracic aortic aneurysms and dissection, TAAD [Pannu, 
H. et al. 2005a; Pannu, H. et al. 2005b].  
The same year the first description of Loeys-Dietz syndrome (LDS) was 
published [Loeys, B. L. et al. 2005]. This is a Marfan-like genetic disorder 
of connective tissue caused by mutations in TGFBR1 and TGFBR2, with a 
high risk of arterial aneurysms and dissections. About one year later, LDS 
was divided into two types, type 1 and type 2 [Loeys, B. L. et al. 2006].  
Recently there have been a number of reports on persons with mutations in 
TGFBR1 and TGFBR2 fulfilling the GC [Disabella, E. et al. 2006; Singh, 
K. K. et al. 2006; Stheneur, C. et al. 2008]. 
For the syndrome in people fulfilling the GC and having mutations in 
TGFBR1 or TGFBR2, but not in FBN1, some articles use the name MFS 
type 2, while others refer to it as LDS type 2. [Arslan-Kirchner, M. et al. 
2008; Stheneur, C. et al. 2008; von Kodolitsch, Y. and Robinson, P. N. 
2007]. They seem to use the name MFS type 1 for individuals fulfilling the 
GC and carrying an FBN1 mutation. Some authors emphasise the 
phenotypic heterogeneity among persons carrying a mutation in TGFBR1 or 
TGFBR2 [Akutsu, K. et al. 2007]. Possibly the clinical spectrum is as wide 
in such persons as in MFS. 
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Results 
Summary of papers 
Paper 1 
Prevalence data on all Ghent features in a cross-sectional study of 87 
adults with proven MFS. 
 
The purpose of this study was to explore the phenotype, that is to estimate 
the prevalence of each ‘major criterion’ and ‘organ involvement’ in an adult 
cohort with a proven diagnosis of MFS. On investigating 105 adults with 
presumed MFS for all features in the GC, it was found that 87 (83%) 
fulfilled the criteria through 56 different combinations of features. Among 
Ghent-positive persons, a major dural criterion was found in 91%, a major 
genetic criterion (positive family history and/or FBN1 mutation) in 89%, a 
major ocular criterion in 62 %, a major cardiovascular criterion in 53% and 
a major skeletal criterion in 38%. In 14 persons (16%), the diagnosis was 
dependent on the dural findings. Seventy-nine per cent fulfilled both major 
dural and major genetic criteria. The prevalence of major ascending aortic 
pathology and that of mitral prolapse are among the lowest reported. The 
study confirms the need for the complete GC to identify all patients with 
MFS. The majority of persons with MFS might be identified by the 
combined assessment of dura mater and family history, supplemented with 
DNA analysis in family negative cases.  
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Paper 2 
Dural ectasia in Marfan syndrome. A case control study. 
 
The purpose of this study was to establish the prevalence of dural ectasia in 
a cohort of patients fulfilling the GC for MFS, and to find the best criteria 
for assessment of dural ectasia. This was done by investigating the 
morphology of the lumbo-sacral spine of 105 adults with presumed MFS 
with MR imaging (unless contraindicated, in which case CT was 
performed). One-hundred and one sex and age-matched persons who had 
been investigated for malignancy constituted the control group. Lumbo-
sacral antero-posterior vertebral body diameters (VBD) and dural sac 
diameters (DSD) were measured. Dural sac ratios (DSR = DSD/VBD) at 
levels L3 through S1 were calculated. Anterior meningoceles, herniations of 
nerve-root sleeves and scalloping were characterized.  
In the study cohort, three patient groups were identified:  
1) Fulfilling GC independently of dural ectasia (n=73)  
2) Fulfilling GC with dependence on dural ectasia (n=14)  
3) Suspected MFS, not fulfilling GC (n=18) 
 
Dural ectasia was found in 86% of group 1. At levels L4-S1, the mean 
DSRs were significantly higher in group 1 than in group 3 and controls (p < 
0.001). Herniations of the nerve-root sleeves were present in 73% of group 
1 compared with 1% of the controls. Anterior meningoceles were found in 
37% and 14% of groups 1 and 2, respectively, but not in group 3 or 
controls. The dural sac was longer and wider in persons fulfilling the GC 
than in those not fulfilling them. The diagnosis of dural ectasia on MR or 
CT imaging should be based on the presence of at least one of the following 
criteria: Anterior meningocele or nerve-root sleeve herniation, DSD at S1 or 
below larger than DSD at L4; DSR at S1 > 0.59. 
 36 
Paper 3 
Search for Correlations Between FBN1 Genotype and Complete Ghent 
Phenotype in 44 Unrelated Norwegian Patients with Marfan Syndrome. 
 
The aim of this study was to test for correlations between FBN1 genotype 
and phenotype, expressed as the presence of major criteria and organ 
involvement in adults with MFS. This was done by sequencing the entire 
coding region of FBN1 and searching for large deletions and duplications in 
105 participants with presumed MFS who had been equally and completely 
examined for all features in the Ghent nosology. We identified 46 mutations 
in 44 unrelated patients (a total of 73 persons with an FBN1 mutation), all 
fulfilling GC. Although no statistically significant correlation was found, 
the data indicate associations between missense or splice site mutations and 
ocular manifestations. While mutations in TGF domains were associated 
with the fulfilment of few major criteria, severe affection was indicated in 
two cases with C-terminal mutations. A striking intrafamilial phenotypic 
variation was observed among carriers of the same mutation 
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Paper 4 
Health-related quality of life in Marfan Syndrome. 
 
Based on clinical observations and on the pilot study, the aim of study 4 
was to investigate health-related quality of life (HRQOL) in adults with 
verified MFS as measured with one of the most commonly used generic 
questionnaires, SF-36 (see methods page 31). A comparison was made with 
the general Norwegian population, with published HRQOL studies in 
chronic disease, and with other studies on MFS. In addition, correlations 
between the subscales of SF-36 and a number of biomedical criteria and 
symptoms of MFS were explored. 
The study cohort consisted of 84 persons with verified MFS defined from 
the cross-sectional study.   
Persons with MFS reported reduced scores on all 8 subscales of SF-36 
compared to the general population; a result comparable to reports from 
other groups of individuals with severe and disabling chronic diseases. 
Compared with earlier SF-36 results from groups with MFS, we found a 
similar health-related quality of life profile, but lower scores on social 
function, vitality, general health, bodily pain and role physical. 
However, there were no correlations of substantial explanatory value 
between the SF-36 subscales and gender, body mass index, ascending aortic 
surgery, β-blockers, visual acuity, joint hypermobility, fulfilment of the five 
major GC and number of major criteria fulfilled.   
 38 
Overall results 
Eighty-seven out of 105 adults with presumed MFS were proven to have 
the syndrome, while the diagnosis was refuted in 13 of the 90 persons who 
had been given the diagnosis earlier and in five of the 15 persons with 
suspected MFS.  
The status for all 105 participants in relation to the GC is presented in table 
2. Capital letters show major criteria fulfilled; small letters show organ 
systems involved. This method for describing the individual findings in 
accordance with the GC will be used in the following text.   
The diagram in Figure 1, page 39 illustrates the overlapping of groups of 
the study population. 
In short, this figure confirms hypotheses 1-4:  
Hypothesis 1: Only a fraction of the presumed MFS population fulfils the 
diagnostic criteria, GC. 
The diagnosis could be refuted in 13 persons who had been given the MFS 
diagnosis earlier, as they did not fulfil the GC.  
Hypothesis 2: Only a fraction of the same population carries a mutation in 
FBN1. 
Of the 87 persons fulfilling the GC, an FBN1 mutation was found in 73 
persons.  
Hypothesis 3: The fraction fulfilling the GC and the fraction carrying a 
mutation in FBN1 does not consist of the same individuals. 
Fourteen participants not carrying an FBN1 mutation fulfilled the GC. 
However, of these 14 persons, two carried a mutation in TGFBR2 and one a 
mutation in TGFBR1 (Table 6).  
Hypothesis 4: There is a range of disorders of connective tissue and other 
diseases in which some of the features of MFS are present, but where the 
GC are not fulfilled. There is a need for better categorisation and tools for 
the differential diagnostics between the Marfan-like disorders. 
No mutation in FBN1 was identified in the 18 persons not fulfilling the GC. 
In five of these persons, a mutation in TGFBR2 was found (Table 6).  
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Because of the family history and a history of uterine rupture, one person 
was further referred for new diagnostic examinations. The diagnosis MFS 
had been given earlier, but no major criteria were fulfilled, and no organ 
systems were involved. Subsequently a mutation in COL3A1 was found, 
confirming the diagnosis of vascular Ehlers-Danlos syndrome (Table 6).  
A participant fulfilling the major ocular criterion and whose skeletal system 
and skin and integument were involved had a high serum homocysteine 
level, confirming homocystinuria. 
We found no participants carrying FBN1 mutations who did not fulfil the 
GC. 
 
Concerning HRQOL, hypothesis 5 is also confirmed: 
Hypothesis 5. People fulfilling the GC for MFS report lower HRQOL than 
the general population. 
Persons with MFS had reduced scores for all 8 subscales of SF-36 
compared to the general population. 
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Fig 1. 105 adult Norwegians with presumed Marfan syndrome 
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Table 2: 105 adult Norwegians with presumed Marfan syndrome distributed 
according to the number of major criteria and number of organ systems 
involved. 
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Discussion 
Through systematic and comprehensive investigations of all features in the 
GC, we identified the true proportion of participants in our study population 
who had MFS according to the current diagnostic criteria. Future studies 
based on this group might contribute to a better understanding of the 
clinical history of MFS. 
Methodological considerations 
Study population 
With the intention of finding a representative MFS population with a 
verified diagnosis in accordance with the GC, a cross-sectional study on a 
cohort from the Norwegian population was established.  
In the literature, some papers present populations from defined 
geographical regions (examples: [Fuchs, J. 1997; Gray, J. R. et al. 1994; 
Mortensen, K. et al. 2009; Rybczynski, M. et al. 2008]). Most published 
studies on MFS have recruited participants from large and often undefined 
areas. Although difficult to obtain, a representative MFS population should 
consist of all patients within a well defined region. 
There were two reasons for investigating adults only: Owing to the age-
dependent evolution of a number of MFS related features, we wanted to 
investigate participants with a fully developed syndrome [Faivre, L. et al. 
2007]. Secondly, undergoing a full investigation could be demanding for 
children, who would be unable to decide for themselves whether they 
wanted to participate or not, and would be dependent on their parents’ 
decision. 
 
The prevalence of MFS in Norway is unknown. Up to now, besides 
registrations in every hospital, the only Norwegian source for identifying 
individuals with MFS has been the TRS database (see page 28). Thus, we 
 42 
do not know either how comprehensive or how representative our patient 
sample is. 
Compared with the reported prevalence in Scotland [Gray, J. R. et al. 1994] 
and in Denmark [Fuchs, J. 1997], we believe that we informed the majority 
of persons with MFS living in Norway through the three ways described.  
 
Of the participants in our study, 64% were women and 36% men; as a 
group the men were somewhat younger, the women somewhat older. The 
skewed representation regarding gender and age possibly constitutes a 
selection bias. Figure 2 illustrates the gender and age of the 105 
participants. 
Figure 2 
Participants, age groups at time of invetigation. 
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The age and gender representation is comparable to that in the study cohort 
recruited by De Bie et al [De Bie, S. et al. 2004] through seven national 
support groups in Europe (55.3% women and  44.7% men, the men being 
younger and the women older) and the cohort studied by Foran et al, 
comprising 22 persons, 17 women and 5 men [Foran, J. R. et al. 2005]. 
One explanation for the skewed selection might be that men are more 
reluctant to seek medical assistance than women. It might be speculated that 
men need more severe signs and symptoms of MFS than the women to be 
motivated for participation in a study. 
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In our study, among persons fulfilling the GC, major cardiovascular criteria 
were significantly more present in men (22/31) than in women (24/56; 
p=0.014). The prevalence of the major criteria for the other four organ 
systems did not differ significantly between genders. This can either be 
interpreted as a consequence of the reluctance of men to seek help (see 
above), or as a true gender difference in the prevalence of cardiovascular 
pathology. The latter explanation may be supported by the finding of Faivre 
et al concerning gender: “Significant differences were found only for the 
cumulative probability of aortic surgery for patients with aortic dilatation. --
--- 46% of males had surgery for aortic dilatation before or at age 40 years 
compared with 34% of females” [Faivre, L. et al. 2007].  
 
We have been informed about one reason for not participating in the current 
study: In Norway, some benefits from the public health care system are 
dependent on having a diagnosis entered on a governmental list; for 
example, there is a list of diagnoses giving the right to physiotherapy 
covered by the public health care system. MFS is on such diagnostic lists 
giving benefits. During the recruiting process, we learned from the patient 
organisation that some members abstained from participation because of 
fear of losing their diagnosis, and thereby losing benefits. 
All persons who signed in for participation during the two years of 
investigations for the study were offered an appointment for investigation. 
Pre-study examinations 
Before the study, none of our participants had been investigated for dural 
ectasia or protrusio acetabuli, and few for blebs in the lungs, skeletal 
features and features in the skin and integument. One participant mentioned 
that a DNA sample had been taken, but we could not find a result.  
According to the literature, incomplete evaluation of persons with MFS is 
quite usual, (see paper 1 table 3). This is also evident from the papers 
published on the basis of the international FBN1 mutation database. These 
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papers provide mutational and available clinical data concerning more than 
1000 persons. In fewer than one-third of the inviduals, had investigations of 
the dura and hips been carried out [Faivre, L. et al. 2007; Faivre, L. et al. 
2008; Faivre, L. et al. 2009a; Faivre, L. et al. 2009b; Faivre, L. et al. 2009c; 
Stheneur, C. et al. 2008; Stheneur, C. et al. 2009] 
Clinical and radiological Investigations 
Most of the investigation methods for the diagnostic part of our study were 
described by the article originally presenting the GC [De Paepe, A. et al. 
1996]. For some features, cut-off limits against normality are not given in 
the paper. Thus, we had to establish such limits for some features. Our 
chosen values are presented in paper 1, table 1. 
At the time of planning, we did not have substantial reasons to include 
intra-venous contrast injection as part of the MRI of the aorta.  
After interpreting and measuring the images, however we changed our 
minds. Pathological features in the descending aorta were found in a large 
number of participants and the quality of the investigations was not optimal. 
Thus we realised that contrast enhancement was indicated. Even today, 
using newer generations of technology, MRI or CT with contrast might 
provide better images of the intra-thoracic aorta. 
Adapted radiological methods 
To examine for the presence of protrusio acetabuli, CT scans of the 
acetabuli were used instead of anterior-posterior X-ray of the pelvis. There 
is no golden standard for examining for protrusio acetabuli. As protrusio 
acetabuli is a spatial change of the shape and position of the acetabulum, we 
believe that CT (and MRI) investigations must be better tools than 2-
dimensional X-ray images. No methods for assessment for protrusio 
acetabuli using CT have been described. Recently, two papers have been 
published, however, one describing a method for assessing protrusio 
acetabuli using MRI [Chen, L. et al. 2009] and one arguing for use of CT or 
MRI in such assessment [Richards, P. J. et al. 2009].  
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Our method might have resulted in a higher prevalence of protrusio 
acetabuli in our study. Studies of normal populations are needed to develop 
methods of examination and to find the normal prevalence. One such study 
is under way by our group. 
In consideration of irradiation exposure, Rybczynski et al advocate use of 
MRI scans instead of radiography or CT [Rybczynski, M. et al. 2008]. This 
supports our choice of MRI for the assessment of dural ectasia, and favours 
the use of MRI for assessment of protrusio acetabuli.   
To examine for blebs in the lungs, CT scans of the thoracic cages were 
chosen instead of plain X-rays. Being able to identify blebs all through the 
lungs may have given a higher prevalence in our study compared with 
studies using X-rays. 
Genetic methods 
The only source of information on the family history and on relatives not 
participating in the study was the participants themselves. As we only 
investigated adults who were presumed to have MFS, the likelihood that 
they had talked to their first-degree relatives about the relative’s signs and 
symptoms of MFS seems to be high. As described on page 30, the only 
information used in the assessment of relatives was information about 
relatives with a known dilated or dissected aorta or who were known to 
have undergone aortic surgery, and who had loose lenses or had had lenses 
removed because of dislocation. None of the relatives was said to have had 
mutational analyses. While collecting the family histories, I got a good 
picture of the level of knowledge of the participants about their first-degree 
relatives. In our cohort, 45 participants were the only representatives from 
their family, while 60 participants represented 21 families. Each of those 60 
persons described their relatives, whether they were participating in the 
study or not. I found no incorrect descriptions of relatives, when talking to 
the described relatives themselves. 
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We consider that our method of sampling data for information on the family 
history will have resulted in a minimum estimate of the number of relatives 
independently fulfilling the GC. We believe the risks for over-estimates are 
low; misinterpretation of the type of operation in relatives operated on for 
mitral valve pathology is one possible reason; misinterpretation of cataract 
surgery as operations for loose lenses another. 
 
Before our study, mutational analysis of FBN1 was not offered in Norway.  
To be able to manage the major work of sequencing  all 65 exons of FBN1 
in 105 participants, the laboratory established a new routine, using a robotic 
system [Tjeldhorn, L. et al. 2006]. Consequently, the analyses were 
accomplished during a relatively short period of time. This would not have 
been possible with use of conventional methods.  
Only the coding parts of FBN1, including the splice sites and nearby parts 
of the introns, have been sequenced in our study. Therefore, all intronic 
mutations might not have been found through sequencing. We cannot 
exclude the possibility that the 10 GC positive participants, in whom no 
mutations were found, may in fact have intronic mutations in FBN1. 
Furthermore, large deletions may not be identified by sequencing. 
Therefore, MPLA analysis was performed.  
 
Discussion of findings 
Out of the 105 participants, 87 participants were assessed as fulfilling GC, 
while 18 were not.  
The vast majority, 76 of the 87 participants (87%) fulfilling the GC, met 
these criteria independently of family history and / or mutation in FBN1. 
This is a higher fraction compared with the finding by Faivre et al that the 
diagnosis of MFS was possible on clinical grounds in 72% [Faivre, L. et al. 
2008]. The difference is probably due to the fact that we investigated the 
dura mater in all cases. 
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Table 3: Seventy-six persons fulfilling the Ghent criteria independently of 
family history and mutation 
 
Table 4: Nine persons: A first-degree relative fulfilling the Ghent criteria, 
one clinical major criterion and at least one organ system involved 
 
Nine persons had a first-degree relative independently fulfilling the GC, one 
clinical major criterion and at least one organ system involved (Table 4). 
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Table 5: Two persons each had an FBN1 mutation, not previously reported, 
and each fulfilled one clinical major criterion and had one other organ 
system involved 
 
Table 6: Green: One person carrying a mutation in TGFBR1. Red: Seven 
persons carrying mutations in TGFBR2. Blue: One person carrying a 
mutation in COL3A1 
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Two persons out of the 87 who met the GC, both the first in their family to 
be assessed for MFS, had a mutation in FBN1, which had not previously 
been reported, and also fulfilled one clinical major criterion (dural ectasia in 
both cases) and had one organ system involved (Table 5). They were the 
only ones to be dependent on DNA sequencing to meet the GC. In 
comparison, Faivre et al reports that 17% in their study were dependent on 
mutational analysis before fulfilling the GC [Faivre, L. et al. 2008] 
However, only 1/3 of their participants were assessed for dural ectasia.   
Four study groups 
Taking the presence or absence of fulfilling GC and of FBN1 mutations into 
consideration, we intended to stratify our study cohort into four groups: 
1. Fulfilling GC, carrying an FBN1 mutation 
2. Fulfilling GC, not carrying an FBN1 mutation 
3. Not fulfilling GC, carrying an FBN1 mutation 
4. Not fulfilling GC, not carrying an FBN1 mutation 
Group 1: Fulfilling GC, carrying an FBN1 mutation. 
Of the 87 participants fulfilling GC, 73 (84%) were carrying an FBN1 
mutation, comparable to the findings reported by others [Loeys, B. et al. 
2004]. 
Among our 44 index cases, we did not find any statistically significant 
correlations between genotype and phenotype (paper 3). This is probably a 
consequence of our small material, as pointed out by Faivre et al [Faivre, L. 
et al. 2007] in their discussion. Nonetheless, our findings indicated that 
missense mutations affecting a cysteine residue were associated with 
ectopia lentis. This is in accordance with the results of Faivre et al, based on 
over 1000 persons with FBN1 mutations [Faivre, L. et al. 2007], who 
verifies earlier findings [Schrijver, I. et al. 1999]. 
 
One person, who fulfilled FDAasi (the major family / genetic, major dural 
and major cardiovascular criteria and with affected cardiovascular, skeletal, 
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and skin and integument systems), met the GC and also had 
craniosynostosis. The family mutation in FBN1 was found, as in the mother 
and a sibling, both of whom fulfilled the GC. The relatives did not have 
craniosynostosis. No mental retardation was present.  
In some reports, craniosynostosis is said not to have been found in MFS1 
and MFS2, while mutations in FBN1 have been present among persons with 
craniosynostosis [Arslan-Kirchner, M. et al. 2008]. Akutsu et al [Akutsu, K. 
et al. 2007] discuss Furlong syndrome and Shprintzen-Goldberg syndrome 
and the two syndromes relation to mutations in TGFBR1 and TGFBR2, but 
not related to mutations in FBN1. Ades et al [Ades, L. C. et al. 2006] 
discuss the presence of craniosynostosis in persons fulfilling the GC, and 
discuss Shprintzen-Golberg Syndrome (mental retardation obligate) and 
Furlong syndrome (no mental retardation) and their relation to MFS and 
LDS syndrome. In a recent paper on genetics of craniosynostosis, mutations 
in FBN1, TGFBR1 and TGFBR2 are mentioned as “also associated with 
craniosynostosis, but --- with an apparently low penetrance” [Passos-
Bueno, M. R. et al. 2008]. Our family mentioned above, all three fulfilling 
the GC and carrying an FBN1 mutation must be said to have MFS. 
Group 2: Fulfilling GC, not carrying an FBN1 
mutation. 
We did not foresee the possibility of persons fulfilling the GC having a 
different diagnosis than MFS. In 14 participants fulfilling the GC, no FBN1 
mutations were found. This indicates genetic heterogeneity in MFS. As 
stated previously, mutational analysis of TGFBR1 and TGFBR2 yielded a 
mutational explanation in three of the 14 cases (Table 6). Those three 
participants were interpreted as having MFS type 2, which many consider 
to represent individuals with LDS type 2 meeting the GC   [Arslan-
Kirchner, M. et al. 2008; Stheneur, C. et al. 2008; von Kodolitsch, Y. and 
Robinson, P. N. 2007] 
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In one of the three participants, tortuous arteries were found at clinical 
follow up.  
In our study, on the basis of facial features and mental retardation one 
person fulfilling DOSs (major dural, major ocular and with the major 
skeletal criteria fulfilled and the skeletal system involved), thus meeting the 
GC, was referred for further investigations, and was later diagnosed with 
Shprintzen-Goldberg syndrome. No mutations were found in FBN1, 
TGFBR1 or TGFBR2. 
Group 3: Not fulfilling GC, carrying an FBN1 
mutation 
We did not find FBN1 mutations in persons not fulfilling the GC.  Thus, in 
our population, we found no other type 1 fibrillinopathies than MFS. 
Papers discussing “other type 1 fibrillinopathies” based on substantial 
numbers of persons have mainly been written on the basis of the FBN1 
mutational database [Faivre, L. et al. 2007; Faivre, L. et al. 2008; Faivre, L. 
et al. 2009b; Stheneur, C. et al. 2009]. These papers are based on the same 
sample of about 1000 persons carrying an FBN1 mutation, with “clinical 
information”. Of those, dural ectasia was sought in 292 persons; and 
protrusio acetabuli in 298 persons.  
In spite of the incomplete data, these papers present a number of persons as 
representatives for “other type 1 fibrillinopathies” This would imply allelic 
heterogeneity of FBN1. However, if a complete investigation with regard to 
the GC, and in particular dural ectasia had been carried out, a different 
conclusion might be drawn. For example Faivre et al [Faivre, L. et al. 
2009b] report on 146 adults who did not meet the GC, of whom 6 were 
assessed for dural ectasia and 5 for protrusio acetabuli.  In our study, dural 
ectasia was present in 91% of persons fulfilling the GC. If this prevalence is 
representative, a large fraction of the 146 adults would probably have dural 
ectasia. As a consequence, they would fulfil the GC.  
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In our opinion, the concept of “other type 1 fibrillinopathies” may be 
premature, and studies of all organ systems in large MFS populations are 
required before firm conclusions can be drawn. This view is supported by 
Pepe et al [Pepe, G. et al. 2007], who found that six out of seven index 
persons diagnosed as having isolated ectopia lentis actually fulfilled the GC 
when all organ systems were investigated. Of the 12 persons who 
underwent MRI of the lumbo-sacral spine, eight were found to have dural 
ectasia. 
Group 4: Not fulfilling GC, not carrying an FBN1 
mutation 
According to hypothesis 4, see Aim of the study, hypothesis, there is a 
range of disorders of connective tissue and other diseases in which some of 
the features of MFS are present, but where the GC are not fulfilled. There is 
a need for better categorisation and tools for the differential diagnostics 
between the Marfan-like disorders. 
 
Eighteen participants did not meet the GC. Of these, 13 had been given the 
MFS diagnosis earlier, while the diagnosis had been suspected in five.  
A total of five participants (fulfilling Aaspi, Aasi (two participants), Aai 
and Dspi), who did not meet the GC and did not have an FBN1 mutation, 
had a TGFBR2 mutation (Table 6). At the time of the clinical investigation, 
LDS syndrome was not known, and the specific features were not looked 
for. Joint hypermobility, stretch marks and stretchable skin were found. 
Thus, the condition was assessed as being LDS type 2. 
As mentioned previously (page 38), one participant who did not fulfil any 
major criteria and in whom no organ systems were involved, carried a 
mutation in COL3A1. 
One participant fulfilling Osi (the major ocular criterion and involvement of 
the skeletal and the skin and integument systems) had high serum 
homocysteine, confirming homocystinuria. 
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On grounds of joint hypermobility, atrophic scarring, stretch marks and 
stretchable skin, a male participant fulfilling Di (major dura with skin and 
integument involved) was given the diagnosis classic Ehlers-Danlos 
syndrome (EDS). No mutations in FBN1, TGFBR1 or TGFBR2 were found. 
In the participant fulfilling Sspi (skeletal major, skeletal system affected, 
pulmonary system affected, and skin and integument affected), a bicuspid 
aortic valve was found. No mutations in FBN1, TGFBR1 or TGFBR2 were 
detected.  
The participant fulfilling FO (the family / genetic major criterion and the 
major ocular criterion) had one lens subluxated. The mother independently 
fulfilled the GC. The mother had the family mutation in FBN1, while the 
participant did not. 
The participant fulfilling F (the family / genetic major criterion), but no 
other pathological criterion, came from a large Marfan family where the 
family mutation was found in all affected members, but not in this person. 
On the basis of joint hypermobility and smooth, velvety skin but no 
atrophic scarring, the four persons fulfilling i; pi (two persons) and Ds were 
assessed as having benign joint hypermobility syndrome (BJHS), now often 
considered to be the same as Ehlers-Danlos syndrome, hypermobile type 
[Tinkle, B. T. et al. 2009]. 
In three persons, no diagnosis was given. One person, who had been 
diagnosed earlier as MFS, did fulfil s (skeletal system involved). No 
pathology was found except a marfanoid habitus. No mutations were 
observed. 
A pair of siblings had both been given the MFS diagnosis. One male was 
assessed as fulfilling Aapo (major cardiovascular system, cardiovascular 
system involved, lungs involved and ocular system involved); no mutations 
were found. The diameter of the ascending aorta was measured 37mm on 
echocardiography, while on MRI it was 32mm. Using the diameter 
measured on echocardiography, the aortic index was 2.08; mitral valve 
prolapse, blebs on the lungs and long ocular bulbs with flat cornea were 
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found. In the sibling, no pathology in accordance with the GC was found. 
Follow-up of the sibling with affected organ systems and suspected aortic 
dilatation has been organized.  
Spectrum among persons with suspected MFS 
The observed clinical and mutational spectrum in our study seems to be 
comparable to the findings by Akutsu et al [Akutsu, K. et al. 2007]. Among 
persons with suspected MFS he found mutations in TGFBR1, TGFBR2 and 
COL3A1. 
Rybczynski et al describe the spectrum of symptoms and manifestations 
among 279 persons with suspected MFS. They report on one mutation in 
TGFBR2 and three persons with vascular EDS [Rybczynski, M. et al. 
2008]; it is not stated whether COL3A1 had been sequenced in the three 
persons clinically diagnosed as having vascular EDS.  
The great variability in the clinical presentation in our study, with 56 
different variants of fulfilment of the GC among the 87 persons meeting the 
criteria, is striking.  
In their above-mentioned report, Rybczynski et al give the prevalence of a 
number of isolated features included in the GC, and state how many of 16 
different features each participant fulfilled. Unfortunately, the authors do 
not report on the prevalence of fulfilment of compound major criteria or 
compound organ systems involved; for example they report how many 
participants had a dilated ascending aorta and how many had ascending 
aortic dissection, but do not report how many participants met the major 
cardiovascular criterion. Likewise, they do not give the prevalence of 
fulfilment of the major skeletal criterion. 
However, they give the sensitivity and specificity of a number of features in 
the GC. This illustrates the large variability within the group fulfilling the 
GC and the high prevalence of the Ghent features among persons with 
suspected MFS but not fulfilling the criteria.  
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Rybczynski et al found highly positive likelihood ratios >10 for facial 
appearance, ectopia lentis, hypoplastic iris or ciliary muscle, and dural 
ectasia, thus supporting our suggestion of using dural ectasia as an early 
diagnostic tool. All negative predictive values were higher than 0.2. They 
therefore conclude that no particular feature can be used to exclude MFS. 
Further, in their group fulfilling the GC, some prevalence rates are 
remarkable: The prevalence of lens ectopia was 44.5 %; dural ectasia 
(assessed in all participants) 45.3 % and stretch marks 41.6 %; all low 
figures compared to our findings. 
Differential diagnostics of connective tissue disorders 
The understanding of the different groups with overlapping features 
resembling MFS has widened the spectrum of differential diagnostics for 
MFS. To quote Arslan-Kirchner et al: “The Marfan- related syndromes are 
an example of allelic and locus heterogeneity. Mutations in a single gene 
can lead to different clinical pictures and similar clinical pictures can be 
caused by mutations in different genes” [Arslan-Kirchner, M. et al. 2008].  
Differential diagnoses of MFS are presented in Figure 3: 
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Figure 3: Differential diagnostics for MFS 
 
 
 
EDS: Ehlers-Danlos syndrome. TAAD: Thoracal aortic aneurysm and 
dissection. MASS syndrome: Myopia, mitral valve prolapse, mild aortic 
dilatation, striae and minor skeletal criteria. 
Diagnostic criteria and congruency between 
diagnostic criteria 
When diagnostic entities are dependent on diagnostic criteria, and they are 
each others’ differential diagnoses, it is important that the criteria are good 
and mutual exclusive; if a person fulfils the criteria for one diagnostic 
entity, he or she should not fulfil criteria for other diagnostic entities.  
For most of the diagnostic entities shown in Figure 3, no diagnostic criteria 
have been found. Diagnostic criteria are published for MFS (the GC) [De 
Paepe, A. et al. 1996], EDS (the Villefranche criteria) [Beighton, P. et al. 
1998] and BJHS (the Brighton criteria ) [Grahame, R. et al. 2000]. These 
three sets of criteria are not congruent in their construction, making 
differential diagnostics difficult. In the Villefranche criteria for EDS, 
generalised joint hypermobility (Beighton score ≥ 5) is a major criterion. 
However, the paper does not state how many major criteria need to be 
Marfan syndrome 1 and 2 
Congenital contractural 
arachnodactyli (Beals’s syndrome) 
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TAAD Familial mitral prolapse 
Vascular EDS 
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fulfilled to give a diagnosis. In the Brighton criteria for BJHS, a history of 
generalised joint hypermobility (Beighton score ≥ 4) is sufficient to fulfil a 
major criterion, while in the GC, joint hypermobility (Beighton score ≥ 4) is 
a minor criterion that might contribute to the skeletal system being 
involved. Furthermore, stretch marks from puberty, thin and stretchable 
skin and wide scars are found in all three groups. Consequently, a large 
proportion of people fulfilling the GC, also fulfil the Villefranche criteria 
and the Brighton criteria. 
Further development of diagnostic criteria for each entity and identification 
of discriminators between the different entities are necessary. 
Differential diagnosis for arterial genetic connective 
tissue disorders 
A current understanding of differential diagnostics for arterial genetic 
connective tissue disorders is outlined in Table 7: 
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Table 7. Differential diagnoses for arterial genetic connective tissue 
disorders 
 
Diagnosis Gene Clinical findings  Criteria 
Marfan 
syndrome FBN1 
Dural ectasia, lens ectopia, asc. 
aortic pathology, chest def., striae Ghent 
Marfan 
syndrome 
type 2 
TGFBR1 
TGFBR2 
Dural ectasia, asc. aortic 
pathology, chest def., striae Ghent 
Congenital 
contractural 
arachno-
dactyly 
FBN2 
Arachnodactyly, scoliosis, 
contractures, chest def., (asc. 
aortic pathology) 
None 
Vascular 
Ehlers-
Danlos 
syndrome 
COL3A1 
Arterial, uterine and intestinal 
ruptures, translucent skin, visible 
veins, hypermobility of small joints 
Ville-
franche 
Loeys-Dietz 
syndrome 
type 1  
TGFBR1 
TGFBR2 
Hypertelorism, bifid uvula and / or 
cleft palate, tortuous arteries. Dil. 
+ dis. large + middle arteries. 
Dural ectasia, hypermobility, 
extensible skin, striae 
None 
Loeys-Dietz 
syndrome 
type 2 
TGFBR1 
TGFBR2 
Like vascular EDS. Dil. + dis. 
large + middle arteries. Tortuous 
arteries. Dural ectasia, 
hypermobility, extensible skin, 
striae 
None 
Familial 
thoracic 
aortic 
aneurysms 
and 
dissections 
(TAAD) 
TAAD1 
Dil. + dis. aorta + large arteries. 
Dominant. Not full penetrance. 
More men than women 
None 
FAA1 
TAAD2 
TGFBR2 
ACTA2 
Familial 
TAAD + 
patent 
ductus 
arteriosus 
MYH11 
Dil. + dis. aorta + large arteries. 
Dominant. Patent ductus 
arteriosus 
None 
Arterial 
tortuosity 
syndrome 
SLC2A10 
Recessive, tortuosity, stenosis, 
dil. large arteries. Dysmorphic 
face, joint laxity, contractures, 
pectus def., arachnodactyly, 
extensible skin  
None 
 
Asc: ascending. Def: deformity Dil: dilated. Dis: Dissected. 
 
 59 
Health-related quality of life in MFS 
The 84 adults fulfilling GC had low SF-36 scores in all eight subscales 
compared to the general population; the findings are comparable to that in 
other diagnostic groups and to the results in three studies on MFS patients.  
At least three factors might have influenced the scores. 
The SF-36 questionnaire was handed out in the evening in hospital after a 
day of blood sampling, echocardiography, clinical evaluation and medical 
history. The participants may have been “primed” on their problems caused 
by MFS, resulting in lower scores on the SF-36.  
It is well known that women usually have lower scores than men. It would 
seem possible that the skewed gender representation, with women in 
surplus, might have resulted in lower scores. Likewise, the age difference 
between our group and the comparison groups might have explained the 
lower scores in some subscales. 
As the chosen control group was matched for age and gender, however, 
these explanations cannot explain the low scores compared to the general 
population.  
The distribution of mean age and gender in the studies used for comparison 
are comparable, with two exceptions (Table 8): The Behçet group, with the 
lowest SF-36 scores among the disease groups, consisted mainly of men, 
and the cystic fibrosis group, in which the male and female representations 
were almost equal, had a lower mean age than the other groups. 
It seems that age and gender cannot explain the low values found in our 
study. 
 
Hypothesis 5 was confirmed: People fulfilling the GC for MFS were found 
to have lower health-related quality of life than the general population. 
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Table 8: Number, mean age and percentage of women in our SF-36 
study and studies used for comparison 
  n Mean age % women 
Our study 84 39 63 
Foran et al [Foran, J. R. et al. 2005] 22 38 77 
Fusar-Poli et al [Fusar-Poli, P. et al. 2008] 36 32 75 
Verbraecken et al [Verbraecken, J. et al. 2001] 15 33 60 
Behçet syndrome [Tanriverdi, N. et al. 2003] 45 34 20 
Cystic fibrosis [Goldbeck, L. and Schmitz, T. G. 
2001] 70 26 54 
Uveitis [Schiffman, R. M. et al. 2001] 76 42 62 
 
(Information about the mean age and gender distribution in the 
Hypertrophic cardiomyopathy study [Cox, S. et al. 1997] is not given for 
the subgroup without chest pain. The total study comprised 137 persons 
older than 14 years (mean age around 42 years), 54% men, divided into 
three groups according to the clinical and family history, including history 
of sudden death). 
 
The low scores in all eight subscales might illustrate the need for 
multidisciplinary treatment of both physical and psychological aspects in 
people with MFS.  
SF-36 studies of larger groups of persons with verified MFS are needed, in 
particular to verify the lacking associations between organ involvement and 
reduced HRQOL as measured by the subscales of SF-36. 
Recently, Volguina et al reported that SF36 version 2 is planned as the 
HRQOL tool in a coming study of valve-sparing versus valve-replacing 
techniques in MFS [Volguina, I. V. et al. 2009]. Our data may become 
important for comparison. 
 61 
Limitations and strengths of the study 
The skewed representation regarding gender and age, with women in 
surplus and men being younger possibly constitutes a selection bias. The 
composition and representativity of the study population has been discussed 
(pages 40-42). 
In the future, recruiting through the departments of medical genetics, 
radiology and thoracic surgery at the university hospitals, through the 
cardiological departments countrywide, through ophthalmological 
departments and ophthalmologists as well as through TRS and the patient 
organisation might provide the basis of a prevalence study.    
The adapted investigational methods may have resulted in a higher 
prevalence of involved lungs and higher fulfilment of skeletal system 
criteria compared with use of conventional methods of examination.  
Although our recruiting method covered a defined population, which was 
intended to give a wider representation than the method often used, the 
population of Norway may be too small to provide a representative sample 
of persons with MFS of all variants and degrees of severity.  
Strengths of our study are: 
 The systematic and complete investigation of all features of the GC  
 All participants examined by the same group of investigators 
 The same methods used in all participants 
 All investigations performed in a reasonably short period (24 
months) 
 The thorough mutational analysis, using robotic methods for 
sequencing of all 65 exons and in addition the search for large 
deletions and duplications   
Another strength is our use of the evolving knowledge. We included a 
search for investigation for mutations in TGFBR2 in all participants, and in 
TGFBR1 in participants in whom no mutations were found in FBN1 and 
TGFBR2. These investigations gave the premises for a wider perspective 
and better differentiation of diagnoses than anticipated. 
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Clinical implications 
Our investigations revealed an insufficiency of the previous diagnostic 
work and we found that a large fraction of our participants had not been 
routinely followed up either by a cardiologist or by an ophthalmologist. 
With the consent of the participants, their clinical reports containing the 
results from all our current investigations and a suggested follow-up plan 
were sent to the participants themselves, and to their general practitioner, 
cardiologist and ophthalmologist.  
This study has demonstrated the benefits for each participant. We have 
therefore also started to use the investigation methods from this study for 
children and adolescents, individually adapting the timing of the different 
investigations in accordance with the maturation of the child.  
As a consequence of this study, the number of persons with MFS in the 
TRS database has increased. For most new persons, we know who fulfils 
the GC and who does not. The diagnostics has been successfully achieved 
using the same methods as in the study.  
Data from 16 September, 2009 show that 205 persons are registered in the 
TRS database as having MFS, 118 women (58%) and 87 men (42%). If this 
figure is used as basis for an estimate, the prevalence will be 4.27:100,000 
inhabitants. Of the 205 persons, 186 persons are 18 years of age or older; of 
these, 109 are females and 77 males.  
Figure 4 illustrates the age and gender distribution of persons registered as 
having MFS in September 2009.  
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Figure 4. 
Registered as Marfan syndrome sept. 2009. N=205
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The personal consequences of MFS are substantial, as measured by all eight 
subscales of SF-36. From a rehabilitation perspective, this illustrates the 
need for better services for people with MFS, focusing on all aspects of life.  
To be able to offer adequate services to each individual with MFS, there is a 
need for diagnostics based on examination of all features of the GC. It is a 
challenge for the clinicians to identify patients with possible MFS, owing to 
the variability of clinical expression.  
The increasing number of MFS-like disorders with different clinical 
histories makes this challenge even greater. This underlines the importance 
of differential diagnostics. A correct diagnosis may be crucial for function 
and life. 
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Future perspectives / future studies  
The diagnostic criteria for MFS should be improved through studies of 
larger groups of people suspected of having the syndrome, with 
investigation of all features of MFS. Producing new diagnostic criteria is a 
task that needs international co-operation. 
Further delineation of – and diagnostic criteria for the MFS-like diagnoses 
are required, with the future intention of describing the clinical features and 
histories of each entity. To achieve this, large descriptive studies need to be 
conducted. The target group should be all patients with MFS-like signs and 
symptoms, recruited from defined geographical areas. All the clinical 
features from the GC as well as features from the descriptive papers 
outlining the new diagnostic entities must be investigated. Known relevant 
genes must be sequenced and DNA copy number variants should be looked 
for. 
Since the description of LDS was published in 2005, the professional co-
workers in this study have identified a substantial number of persons with 
mutations in TGFBR1 and TGFBR2. A Norwegian descriptive study should 
be performed. 
For patients with less frequent disorders of connective tissue, larger 
geographical areas are needed. One possibility is to plan a cooperative 
study covering the Scandinavian countries. The Scandinavian populations 
are being well monitored and documented, so follow-up over some years is 
possible, and the health service systems are able to carry out such a task. 
Clarification of the disputed prevalence of MFS is important. Using the 
investigation methods from this study and recruiting through the user 
organisation, the university hospital departments of medical genetics and 
thoracic and vascular surgery, and through cardiologists and 
ophthalmologists, a full prevalence study based on the Norwegian 
population is within reach.  
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There is a need for new studies of the clinical history of MFS based on 
modern methods of intervention – pharmacological, surgical and lifestyle. 
As part of such studies, our study should be repeated with investigation of 
all features of the GC 10 years after the first investigations.   
There is an unequivocal need for studies on “how to live with MFS”. 
Future studies should be based on complete diagnostic assessment in 
accordance with the GC, thereby making contributions to the clinical 
history of MFS. After finding verified MFS populations, qualitative as well 
as quantitative studies must be undertaken. Through knowledge about the 
clinical history of MFS and studies exploring how life is experienced by 
people with MFS, we can improve services for this diagnostic group.  
Conclusions 
The diagnostic criteria for MFS should be improved through studies of 
larger groups of people suspected of having the syndrome, with 
investigation of all features of MFS. Producing new diagnostic criteria is a 
task that needs international co-operation. 
Although our study indicates that close to 80% of individuals fulfilling the 
GC might be identified through investigation of the dura mater and the 
family history, and when the family history is negative, sequencing of 
FBN1, we conclude that investigation of all GC features is necessary for 
identifying all persons fulfilling the GC. Comprehensive diagnostics are 
necessary for surveillance as well as for the understanding of the clinical 
history of MFS, and a prerequisite for studies of function and the human 
consequences of MFS. Measured with SF-36, the HRQOL in MFS seems to 
be even more reduced in all eight subscales than has been found in earlier 
studies on small study populations. 
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Abstract:  
Background: Marfan syndrome, diagnosed by the Ghent criteria, is 
characterized by affection of many organ systems. The consequences of 
Marfan syndrome on health related quality of life have not been sufficiently 
explored. 
Purpose: To explore health related quality of life in adults with verified 
Marfan syndrome; compare with the normal population, with other patient 
groups with similar chronic problems, and with other studies on Marfan 
syndrome and to explore potential correlations between the subscales of 
Short Form 36 (SF-36) and a number of biomedical criteria and symptoms 
of Marfan syndrome. 
Method: Cross sectional study; health related quality of life as measured 
with SF-36 was investigated in 84 adults with verified Marfan syndrome. 
Results: Persons with Marfan syndrome reported reduced scores on all 8 
subscales of SF-36 compared to the normal population; similar to what is 
reported from other groups of individuals with severe and disabling chronic 
diseases. 
Compared to earlier papers on SF-36 in Marfan syndrome, we found a 
similar health related quality of life profile, but lower scores on social 
function, vitality, general health, bodily pain and role physical. 
We did not find correlations of substantial explanation value between the 
SF-36 subscales and gender, BMI, ascending aortic surgery, β-blockers, 
visual acuity, joint hypermobility, fulfilling the five major Ghent criteria 
and number of major criteria fulfilled.  Different potential explanations are 
discussed. 
Conclusion: Persons with Marfan syndrome reports reduced scores on 
health related quality of life as measured with SF-36, comparable to other 
chronic disorders and disabilities. The reduction seems not to be related to 
biomedical criteria and symptoms of Marfan syndrome. 
 
Key words: FBN1, Health related quality of life, Marfan syndrome, SF-36,  
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Background: 
Marfan syndrome (MFS) is an autosomal dominant connective tissue 
disorder, resulting in variable pathology and symptoms from different organ 
systems. MFS is diagnosed by the Ghent criteria [1], defining  “involved 
organ systems” and “major criteria fulfilled”. To be given the diagnosis, a 
person must fulfill two major criteria in two different organ systems and 
have a third organ system involved. About 30% of the cases are due to new 
mutation.   
 
The impact of MFS on the individual patient may vary considerably both 
between families and within a family. As aortic disease may result in early 
death, some patients will have to cope with an impending life threatening 
condition. Lens dislocation may result in reduced visual acuity and even 
blindness. The consequences of dural ectasia are still unclear [2]; orthostatic 
headache due to cerebrospinal hypotension has been found [3,4]; problems 
with spinal and epidural anesthesia have been reported [5]. Skeletal 
abnormalities may include long, slender body shape, chest deformities, 
scoliosis and joint hypermobility, and may result in a particulate 
appearance. Children with MFS often look older than their chronological 
age. They are often treated in accordance with their appearance, rather than 
their actual age. Individuals with MFS have been bullied and stigmatized in 
the school society, local environment and in their occupational life [6]. 
Moreover, persons with MFS often report musculoskeletal pain, fatigue and 
reduced physical endurance [7,8]. 
 
In the clinic, persons with MFS usually report few, if any, physical 
limitations from their cardiovascular system. On the other hand, physicians 
often advice abstinence from strenuous exercise and prescribe beta-blockers 
to reduce blood pressure and hearth rhythm in order to delay aortic dilation 
and reduce the risk for aortic dissection. Some patients go through 
prophylactic elective graft operations for enlarged aortas. Through such 
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measures, the median life expectancy for persons with MFS has been 
prolonged considerably [9]. To reduce the risk for lens dislocation and 
retinal detachment, the patients are advised not to participate in contact 
sports, and to wear glasses when sporting with small balls. It is our clinical 
experience that the advised restrictions have often resulted in passivity; a 
sedentary life with increasing body mass index.  
 
Given the broad range of symptoms and characteristics among individuals 
with MFS, one would expect reduced health related quality of life 
(HRQOL). Judging from the MFS literature, the severity of aortic disease 
could potentially be the most important predictor for the degree of 
reduction. There are, however, few studies of HRQOL in the literature on 
MFS. In a study of 174 adults with MFS, Peters et al. reported the overall 
quality of life to be adequate, but significantly decreased within the 
psychological domain, with a particular emphasis on the effects on 
reproductive decision-making [10]. In three studies the Short Form 36 (SF-
36) questionnaire [2,11,12] was applied, but the patient groups were small 
(36 persons with MFS [11],  22 persons with MFS and dural ectasia [2] , 
and 15 persons with MFS primarily assessed for sleep apnoea [12]). In all 
three studies, lower levels of SF-36 scores than in healthy controls were 
found. However, the interpretations diverge. In these studies the potential 
associations between fulfilling the different major criteria and subscales of 
SF-36 have not been explored. In our ongoing MFS studies, we therefore 
included one of the most commonly used generic questionnaire, SF-36, 
often applied as a measure of HRQOL. There is an ongoing discussion on 
what is actually measured by SF-36, but that debate is beyond the scope of 
this paper.  
 
Hypotheses: 
By using the Short Form 36, 1) we expected lower SF-36 scores, indicating 
lower HRQOL, in the domains mental health (MH), social functioning (SF), 
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emotional role functioning (RE), vitality (VT), general health (GH), bodily 
pain (BP), physical functioning (PF), and role physical functioning (RP) in 
our MFS sample compared to healthy controls. 2) We expected the 
proposed lower levels in SF-36 scores to be associated with higher age, 
female gender, higher body mass index (BMI), ascending aortic surgery, 
use of β-blocker, reduced visual acuity, joint hypermobility, the five major 
Ghent criteria and number of major criteria fulfilled.   
 
Thus, the purpose of this study was to investigate HRQOL of adults with 
verified MFS, and 1) to compare the results to a gender and age matched 
control group from the Norwegian general population. 2) Compare the 
results with other chronic disorders with similar problems. 3) Compare the 
results with the results of contemporary studies on MFS. 4) Explore the 
associations between the eight subscales of SF-36 with demographic 
variables, MFS symptoms and criteria.  
 
Participants and Methods  
In the Norwegian Marfan study, 105 adult Norwegians with presumed MFS 
were prospectively investigated for all features in the Ghent Criteria [1] by 
the same group of investigators. Eighty-seven of these fulfilled the Ghent 
criteria, and details about the investigations and results are previously 
presented [13-16]. Eighty-four out of 87 persons answered the SF-36 
questionnaires completely (63% women, median age 42 years (range 20-
69); 37% men, median age 35 years, (range 19-69)). Three female subjects 
did not complete the questionnaires and were excluded from further 
analysis (age 32 to 54 years). 
 
A control group (GP) was drawn from a SF-36 dataset from the general 
population (Norwegian Social Science Data Service; “Level of living 
2002”) for comparison. For each person in the study group, five persons 
from the general population were drawn, matched for age and gender. 
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In addition, results from studies of patient cohorts with the following 
significant chronic disease in the same age group, were selected for 
comparison: Uveitis [17], in order to compare for the risk of permanent 
reduced visual acuity; hypertrophic cardiomyopathy (HCM) [18] without 
angina in order to compare the impact of anxiety for early cardiovascular 
death; cystic fibrosis (CF) [19] and Behçet syndrome (BS) [20] were chosen 
for comparison regarding chronic illness. 
 
The SF-36 version 1, taken from the Medical Outcome Study (MOS) is a 
widely used questionnaire interpreted as a valid and reliable measure of 
HRQOL. It consists of 36 questions covering eight subscales. There are 
four subscales in the psychological/mental domain: mental health, role 
functioning emotional, social functioning and vitality; and four subscales in 
the physical domain: general health, bodily pain, physical functioning and 
role functioning physical. The scoring range of all subscales in SF-36 go 
from 0 to100, with100 as the best score [21]. Mean scores may be reported 
for each individual subscale and for two sum scores, the mental (MCS) and 
physical (PCS) component summary. 
 
Statistics 
All data were stored in a customized database (applying SPSS for Windows 
version 13) for description and statistical analyses. SF-36 data were scored 
according to the manual [21]. Independent sample t-test was used to 
compare the MFS group with the GP group. The results were additionally 
controlled by using the Mann-Whitney U test. To assess the size of the 
difference between the MFS group and the GP group, standard difference 
score (s-scores) were calculated. The mean scores of the Marfan group were 
subtracted from the mean scores of the GP; the differences were divided by 
the standard deviation of each scale in the GP. The values of the s-scores 
were interpreted according to Cohen’s effect size index, in which <0.2 
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refers to small difference, 0.5 to 0.8 to moderate, and >0.8 to large 
difference [22]. 
Linear regression analyses were applied to assess the relationship between 
the eight subscales of the SF-36 scores with demographic variables, MFS 
symptoms and criteria as independent variables. For each subscale, multiple 
regression models were applied, using age, gender and the factors showing 
significant correlations in the linear models as independent variables. 
p-values< 0.05 were considered as significant.  
 
Results  
Table 1 shows the characteristics of the study group. The most frequently 
fulfilled major criterion was the dural, followed by the family/genetic, 
ocular, cardiovascular and skeletal criteria.  
Table 2 shows the mean scores in all eight subscales of SF-36 for the MFS 
group and the GP group. There were large differences between the groups, 
with lower scores on all four physical health subscales, as well as on vitality 
and social functioning from the mental health subscales, with effect sizes 
0.81 to 1.52, the latter value in the subscale of general health. There were 
moderate differences in the same direction between the groups for the last 
two subscales within the mental domain; mental health and role emotional, 
with effect sizes of 0.58 and 0.68, respectively.  
The difference in reported HRQOL between the MFS group and other 
groups of persons with chronic disorders as well as between our MFS group 
and other studies concerning MFS are visualized graphically by using the 
mean scores for each subscale (Figure 1 and 2), and further by using mean 
scores MCS and PCS (Figure 3). 
Figure 1 shows the comparison between the eight subscales of the SF-36 for 
the MFS sample and the four chosen chronic disorders. Persons with MFS 
reported lower HRQOL both in physical and mental subscales compared to 
groups of persons with uveitis, CF and HCM. Compared to the group with 
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BS, the MFS group scored higher on all subscales but vitality, for which the 
two groups were similar. 
Figure 2 shows comparisons of the SF-36 scores for our MFS sample 
versus results from the two previously presented studies on MFS (fig. 2). 
Fig. 3 compares the mean MCS and mean PCS for the papers reporting 
component summaries. 
Table 3 reports the final multiple regression models including age, gender 
and the variables with significant contributions to the variances.  
In the final models, there were no significant relationships between gender 
and any of the eight subscales of SF-36. Increasing age was associated with 
increasing pain and decreasing physical function. Fulfilling an increasing 
number of major criteria was associated with better scores for role 
emotional and social function, while having a first degree relative 
independently fulfilling the Ghent criteria and fulfilling the family / genetic 
major criterion were associated with better scores for role emotional. 
Finally, fulfilling the ocular major criterion was associated with higher 
scores for general health and physical function  
 
Discussion 
In this sample of MFS, as expected, we found significantly decreased 
HRQOL on all SF-36 subscales compared to results from a gender and age 
matched general population (GP) drawn from the Norwegian population 
(hypothesis 1). However, the expected associations between the eight 
subscales of SF-36 and the chosen variables were not found (hypothesis 2). 
 
The differences between scores in the MFS sample and the healthy controls 
concerning the physical health subscales, vitality and social function were 
large, while we found moderate differences in mental health and role 
emotional subscales.  
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Comparison groups 
All five disease groups display a similar pattern for the physical subscales, 
with lower general health and role physical scores. Conversely, the SF-36 
profile of the GP is characterized by high scores on all physical subscales.  
With the exception of the BS group, all groups, including the GP, show a 
marked dip in vitality scores as compared to the other mental health 
subscales. The lowest sub-scale score for the BS sample is the role 
emotional subscale.  
In the present study, persons with MFS scored somewhat lower than all 
other groups except the BS sample on social functioning and lower than all 
groups on the vitality subscale. The low vitality score may reflect the often 
presented complaint of fatigue and reduced physical endurance among 
persons with MFS [7]. 
On the physical subscales, MFS persons report more bodily pain and worse 
role physical compared to groups with Uveitis, CF and HCM, but better 
than BS. In our population, 53% of persons fulfilling the Ghent criteria 
have a Beighton score ≥ 4. Consequently, joint hypermobility can only 
explain part of the elevated pain level reported.  
Both Fusar-Poli et al.[11], who investigated persons with MFS only, and 
Verbraecken et al.[12], who investigated sleeping problems in persons with 
Ehlers-Danlos syndrome and MFS, report scores for all eight subscales of 
SF-36. Fusar-Poli et al. also reports mental and physical component 
summaries. Foran et al.[2], who investigated persons with MFS and dural 
ectasia, report the component summaries only. Since over 90% of our study 
population had dural ectasia, comparison to the results of Foran et al seems 
relevant.  
All MFS studies cited report SF-36 profiles similar to findings from the 
comparison groups reported above (fig. 2); the most deviant finding is the 
low score for vitality in our study sample. For physical scores, our study 
sample reports the lowest scores in all subscales but physical function.  
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When comparing SF-36 component summaries, our findings for MCS are 
comparable to the results from Fusar-Pol et al and Foran et al. For PCS, our 
results are comparable to the findings of Foran, but lower than the findings 
of Fusar-Poli.  
The interpretations of the findings are different in the respective studies. 
Fusar-Poli et al. interpret reduced scores on the mental subscales and about 
normal scores on the physical subscales when comparing to the general 
Italian population. They refer to papers reporting a correlation between 
MFS and psychiatric syndromes and neuropsychological deficits (learning 
disabilities). Clinically, we do not find increased prevalence of depression 
and schizophrenia in the Norwegian MFS population. However, in our pilot 
study [23], exploring fatigue, psychological distress and neuropsychological 
function, we found high levels of fatigue, correlating to increased 
psychological distress. 
Verbraecken et al.[12] claim that emotional or psychological problems 
might not be important for sleep disturbances, as scores for emotional 
problems were normal; even though the paper reports significantly lower 
scores for mental function compared to the controls. A significantly low 
score for pain is also reported.  
One may speculate whether the discrepancies between the studies reflect 
differences in recruiting routines, national differences in perception or 
communication of function and pain, or real differences in HRQOL. Where 
the other studies have recruited their participants through specialist 
institutions, our study sample represents a rather unselected group of people 
fulfilling the Ghent criteria, recruited through all relevant specialties and the 
patient organization. 
 
Associations of HRQOL to demographic variables and MFR symptoms and 
criteria: 
Few associations were found between HRQOL and other variables. Of the 
found associations, the effect of increasing age on physical function and 
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role physical are well known. However, whereas most studies find that 
women report lower scores on SF-36, we found no gender difference in our 
MFS sample, which perhaps may be interpreted to suggest that the male 
participants are more seriously afflicted than the females.  
The effect of increasing number of major criteria fulfilled, positive 
family/genetic major and having a 1. degree relative independently 
fulfilling Ghent may at first sight seem surprising.  
Severity in MFS may be understood as fulfilling many major criteria [14]. 
We actually expected that persons fulfilling many major criteria would 
report more reduced HRQOL than persons fulfilling few major criteria. 
However, a study on post polio syndrome reported positive consequences of 
severe polio sequels through identification with the diagnosis [24]. It may 
be easier to adapt to the “Marfan role” when the diagnosis is unquestionable 
or if you have a close relative with the diagnosis. 
The association between (sub) luxated lenses and increased general health 
and physical function are more difficult to explain, and may be spurious 
associations. The fact that no associations were found between any of the 
subscales of SF-36 and visual acuity supports this interpretation. 
The lack of correlations of substantial explanatory value between the 
subscales of SF-36 and most of the independent variables was surprising. 
Contrary to our expectations, we found no association between the 
subscales of SF-36 and important physical symptoms as aortic pathology, 
dural ectasia or fulfilling skeletal major criteria. 
 
We will mention three different, but potentially reconcilable, explanations 
for this result.  
First, the Ghent criteria are complex, demanding at least two major criteria 
to be fulfilled and a third organ system involved. Consequently, “fulfilling 
the Ghent criteria” and “a single major criterion” are hardly independent 
concepts. As all reported persons do fulfill the Ghent criteria, the lack of 
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correlations between these criteria and HRQOL may be a natural 
consequence.  
Second, the diagnosis implies severe pathology in at least three organ 
systems. The perceived consequences vary considerably through 
mechanisms that may not be caused by the pathology described in the 
diagnostic criteria. The SF-36 scores might instead reflect the total burden 
of the syndrome rather than the burden of any specific single symptom. 
Fatigue and reduced physical endurance[23] together with aspects of 
activity of daily living, like coping with stigma [6], pain [2,12], fatigue [2], 
reproductive planning [10], adherence to medication [25] and restrictions in 
physical activity [26] may play a role. Moreover, the relatively low 
HRQOL scores might reflect the burden of living with a lifelong, potential 
disabling and potential life-shortening disease, where the needs for physical 
restrictions and medication are usually not based on perceptions of 
symptoms, but on advice from medical specialists.  
Third, HRQOL may be related to an underlying, general biological 
mechanism associated with disorders of connective tissue such as MFS, 
potentially responsible for the degree of disease severity. This might be in 
accordance with the finding of TGFβ over-signaling as the biochemical 
cause of most MFS pathology found in studies of Marfan-mice [27]  
 
Limitations of our study 
The study cohort is skewed for gender, women being in surplus. Although 
recruited from all specialities, from TRS and from the patient union, the 
sample may be to small to represent all variants of MFS. 
 
Conclusion: 
Persons with verified MFS report a lower HRQOL as measured by all eight 
subscales of SF-36 compared to the Norwegian normal population; the 
physical subscales were somewhat more affected than in the mental 
subscales.  
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The level of SF-36 score decrease is comparable to what is reported by 
other groups of persons with serious chronic disorders. 
Compared to earlier papers on SF-36 in MFS, our study population reports 
lower scores for vitality, bodily pain and role physical. 
Several hypotheses may explain the lack of significant correlations of 
substantial explanatory value between the subscales of SF-36 and 
demographic variables, MFR symptoms and criteria. The complexity of the 
Ghent criteria, the effect of the total burden of the diagnosis, the effect of 
restrictions and medication given prophylactic by professionals, not induced 
by bodily perceptions and an inborn effect of TGFBR- over signaling are 
mentioned. 
Further studies on groups of adults with verified MFS should be pursued to 
explore the consequences of living with MFS. 
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Table 1. 
Characteristics of the study population with Marfan syndrome (MFS). 
N=84 
Age (years), median (range) 39.6 (19-69) 
Women n (%) 53 (63) 
Body mass index, median (range)  24  (15-36) 
Ascending aortic surgery n (%) 29 (35) 
β-blockers n (%) 45 (54) 
Median visual acuity best eye (range)* 0.095 (-0.2 – 2.0) 
Beighton score, median (range) 4 (0-8) 
Fulfil dural major n (%) 76 (91) 
Family/genetic major. n (%) 74 (88) 
1. degree relative fulfils Ghent criteria independently n (%) 53 (63) 
FBN1 mutation found n (%) 70 (83) 
Fulfil ocular major n (%) 52 (62) 
Fulfil cardiovascular major n (%) 46 (55) 
Fulfil skeletal major n (%) 32 (38) 
Number of major criteria fulfilled. median (range) 3.4 (2-5) 
visual acuity logMAR. Normal visual acuity = 0.0;  
visual acuity 1.0 equals0.1 using Snellens method. 
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Figure 1. 
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pain)
CF n=70 (mean age 25,5)
Behçet n=45 (mean age 33,7)
Uveitis n=76 (mean age 42,3)
 
 
Figure 1. Comparison between the mean SF-36 subscales for the MFS 
sample and mean scores for four chronic disorders.  
MFS: Marfan syndrome. GP: General population. HCM: Hypertrophic 
Cardiomyopathy. CF: Cystic fibrosis. Behçet: Behçet syndrome 
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Figure 2. 
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Figure 2. Comparison between the mean SF-36 subscales for the MFS and 
the mean scores for the two studies on MFS reporting the eight subscales. 
 
Figure 3 
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Figure 3. Comparison between the SF-36 mean mental component score 
(MCS) and mean physical component score (PCS) and the mean scores for 
the two studies on MFS reporting mean component scores. 
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